SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A sharp breakout to fresh 52-week highs has traders focused on the upcoming Q3 report and whether BRIUMVIs sales growth will support the move. Buyout and short-squeeze speculation is adding to the bullish chatter, but no deal is confirmed.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. The firm offers annealing and gate-model quantum computing technologies. It provides professional services that assist customers in identifying and implementing quantum computing applications and selling quantum computer systems to customers. The company was founded by Eric Ladizinsky in 1999 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave shares are drawing attention amid a steep selloff and repeated lows, with traders debating whether the decline reflects broad weakness in speculative quantum stocks or concerns about high valuations, losses, and the distance to commercial profitability. Bearish sentiment is prominent, though some investors view the drop as a buying opportunity; the upcoming quarterly report is seen by some as a test of the business case.

C3.ai, Inc. engages in the provision of enterprise artificial intelligence software for digital transformation. It delivers the C3 AI suite for developing, deploying, and operating large-scale AI, predictive analytics, and Internet of Things applications in addition to a portfolio of turn-key AI applications. It operates through the following geographical segments: North America, Europe, The Middle East, and Africa, Asia Pacific, and Rest of World. The company was founded by Thomas M. Siebel, Patricia A. House and Stephen Maurice Ward, Jr. on January 8, 2009 and is headquartered in Redwood City, CA.

C3.ai Inc - Ordinary Shares - Class A

C3.ai Inc

A Northland upgrade citing C3 Code as a potential growth driver for agentic AI has renewed interest in C3.ai, alongside unusual call-option activity and short-squeeze speculation. Traders are divided between optimism about the product and enterprise AI demand, and concern over declining revenue and continued losses.

Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company, which engages in the provision of treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.

Kyverna Therapeutics Inc.

Kyvernas durable one-year miv-cel results in stiff-person syndrome, alongside longer-term myasthenia gravis data, are driving discussion as the company advances its rolling BLA for SPS. Traders are split: some see the findings as strengthening the case for approval, while others cite the stocks weak reaction, small study sizes, safety questions and possible dilution as reasons for caution.

Aduro Clean Technologies, Inc. engages in the manufacture of oils and specialty chemicals using waste plastics. It focuses on hydrochemolytic technology to transform post-consumer polymer waste into a resource for the circular economy. It also develops a novel chemical conversion process to transform waste plastics and low grade renewable oils into renewable fuels and specialty chemicals. The company was founded on January 10, 2018 by Ofer Vicus and William Marcus Trygstad and is headquartered in London, Canada.

Aduro Clean Technologies Inc

Aduros reported pilot results showing high condensable-hydrocarbon yields across polypropylene and mixed polyolefin feeds are driving discussion, alongside progress toward its planned first-of-a-kind facility. Bulls see the results and engineering work as validation of its plastics-recycling technology, while skeptics argue that yields do not establish commercial economics or scalability.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomms sharp decline is being discussed mainly as part of a broad semiconductor selloff following Intels weak outlook, with traders also noting bearish put-heavy options activity. The community is split between treating the drop as a buying opportunity and worrying about further downside ahead of Qualcomms earnings report.

REalloys, Inc. is engaged in the rebuilding of domestic supply chain resilience for rare earth elements and magnets. It is involved in recycling, mining, oxide production, metallization, alloying, and magnet manufacturing. The company was founded on October 4, 2011 and is headquartered in Boca Raton, FL.

REalloys Inc.

Discussion centers on REalloys potential role in a North American rare-earth and magnet supply chain, with traders pointing to U.S. defense sourcing restrictions taking effect in 2027 and the companys Army-linked Tooele project and Tanbreez offtake as longer-term catalysts. Bulls see strategic demand upside, while bears focus on the lack of recent operational updates, execution and dilution risks, and sharp volatility.

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Reports that Innodata laid off roughly 550 workers in India, with additional cuts reported in the Philippines, have fueled concern that a client project was scaled back and could affect revenue. Traders disagree over whether the cuts signal lost customer work or operational efficiency, and are looking to management and quarterly results for clarification.

ON Semiconductor Corp. engages in the provision of intelligent power and sensing solutions with a primary focus on automotive and industrial markets. It operates through the following segments: Power Solutions Group (PSG), Analog and Mixed-Signal Group (AMG), and Intelligent Sensing Group (ISG). The PSG segment offers discrete, module, and integrated semiconductor products that perform multiple application functions, including power switching, signal conditioning, and circuit protection. The AMG segment designs and develops analog, mixed-signal, power management integrated circuits, sensor interface devices, power conversion, signal chain, and voltage regulation devices. The ISG focuses on the design and development of complementary metal oxide semiconductor image sensors, image signal processors, single photon detectors, including silicon photomultipliers, single photon avalanche diode arrays, and short-wavelength infrared products, as well as actuator drivers for autofocus and image stabilization. The company was founded on July 4, 1999 and is headquartered in Scottsdale, AZ.

ON Semiconductor Corp.

Discussion is focused on onsemis emerging AI/data-center exposure: traders point to growth in the Other end-market category, which includes computing and data centers, but question how durable that demand is because long-term supply agreements can be changed or canceled. The debate is tempered by the companys continued exposure to automotive and industrial markets facing a cyclical slowdown, alongside the stocks recent weakness.

Lennar Corp. engages in the provision of real estate related financial and investment management services. It operates through the following segments: Homebuilding, Financial Services, Multifamily, and Lennar Other. The Homebuilding segment refers to the construction and sale of single-family attached and detached homes and the purchase, development, and sale of residential land directly and through entities. The Financial Services segment focuses on mortgage financing, title, and closing services for buyers. The Multifamily segment is involved in the development, construction, and property management of multifamily rental properties. The Lennar Other segment includes funds, asset management platform, and strategic investments in technology companies. The company was founded in 1954 and is headquartered in Miami, FL.

Lennar Corp. - Ordinary Shares - Class A

Lennar Corp.

Berkshire Hathaways large disclosed stake in Lennar has drawn attention, with bulls viewing the buying as a vote of confidence while others question whether it signals a bottom. The bullish case is offset by weak results and a lowered delivery outlook amid high mortgage rates, plus Hunterbrooks allegations about Lennars transactions with its Millrose spinoff, which have raised concerns among traders.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

12 Health Care Stocks Moving In Thursday's Intraday Session

Gainers

Regencell Bioscience (NASDAQ:RGC) stock increased by 30.4% to $10.58 during Thursday's regular session. The company's market cap stands at $4.0 billion.
SenesTech (NASDAQ:SNES) stock rose 24.93% toread more...

12 Health Care Stocks Moving In Wednesday's Intraday Session

Gainers

Can Fite Biopharma (AMEX:CANF) shares rose 43.8% to $4.27 during Wednesday's regular session. The company's market cap stands at $6.3 million.
Regencell Bioscience (NASDAQ:RGC) stock moved upwards byread more...

Bronstein, Gewirtz & Grossman LLC Urges Regencell Bioscience Holdings Ltd. Investors to Act: Class Action Filed Alleging Investor Harm

Bronstein, Gewirtz & Grossman LLC Urges Regencell Bioscience Holdings Ltd. Investors to Act: Class Action Filed Alleging Investor Harm Bronstein, Gewirtz & Grossman LLC Urges Regencell Bioscience Holdings Ltd. Investors to Act: Class Action Filed Alleging Investor Harm PR Newswire NEW YORK, June...

Regencell Deadline Today: Rosen Law Firm Urges Regencell Bioscience Holdings Limited (NASDAQ: RGC) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers and acquirers of Regencell Bioscience Holdings Limited (NASDAQ: RGC) securities between October 28, 2024 and October 31, 2025, inclusive (the Class Period). Regencell is a purported...

RGC Shareholder Alert: June 23, 2026 Lead Plaintiff Deadline in Regencell Bioscience Holdings Limited Securities Class Action - Contact The Gross Law Firm

RGC Shareholder Alert: June 23, 2026 Lead Plaintiff Deadline in Regencell Bioscience Holdings Limited Securities Class Action - Contact The Gross Law Firm RGC Shareholder Alert: June 23, 2026 Lead Plaintiff Deadline in Regencell Bioscience Holdings Limited Securities Class Action - Contact The...

RGC FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Regencell Bioscience (RGC) Investors of Securities Class Action Lawsuit Deadline on June 23, 2026

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Regencell Bioscience Holdings Limited (Regencell or the Company) (NASDAQ: RGC) and reminds investors of the June 23, 2026 deadline to seek the role of lead plaintiff in a federal securities class...

Deadline Soon: Regencell Bioscience Holdings Limited (RGC)Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit

The Law Offices of Frank R. Cruz reminds investors of the upcoming June 23, 2026 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Regencell Bioscience Holdings Limited (Regencell or the Company) (NASDAQ: RGC...

RGC EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Regencell Bioscience (RGC) Investors of Securities Class Action Lawsuit Deadline on June 23, 2026

RGC EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Regencell Bioscience (RGC) Investors of Securities Class Action Lawsuit Deadline on June 23, 2026 RGC EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Regencell Bioscience (RGC) Investors of Securities Class Action Lawsuit Deadline on...

SueWallSt Reminds Regencell Bioscience Holdings Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of June 23, 2026 - RGC

SueWallSt Reminds Regencell Bioscience Holdings Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of June 23, 2026 - RGC SueWallSt Reminds Regencell Bioscience Holdings Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of June 23, 2026 - RGC PR...

Pomerantz Law Firm Announces the Filing of a Class Action Against Regencell Bioscience Holdings Limited and Certain Officers - RGC

Pomerantz Law Firm Announces the Filing of a Class Action Against Regencell Bioscience Holdings Limited and Certain Officers - RGC Pomerantz Law Firm Announces the Filing of a Class Action Against Regencell Bioscience Holdings Limited and Certain Officers - RGC PR Newswire NEW YORK, June 18, 2026...

Regencell Bioscience Holdings Ltd. is a early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder. The company was founded by Yat-Gai Au on October 30, 2014 and is headquartered in Hong Kong.

Regencell Bioscience Holdings Ltd

RGC Stock Gains 20% Pre-Market — Retail Says Shorts Are In ‘Huge Trouble’

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>Regencell stated in an October SEC filing that it may be required to curtail or discontinue its operations in the future.</li><li>In the 2025 and 2024 fiscal years, Regencell reported a net loss of $3.58 million and $4.36 million, respectively.</li><li>The company had indicated that it anticipates incurring additional losses before realizing any revenues.</li></ul>Shares of Regencell Bioscience Holdings (RGC) have been drawing significant investor attention after gaining nearly 152% in the first four trading sessions of 2026.Following Wednesday’s relentless rally, the shares continued to climb in Thursday’s pre-market trade as well, rising by over 20% at the time of writing.While the bulk of the recent surge has come in 2026, RGC stock is still up nearly 218% since October 31, despite the company flagging a “substantial doubt” about its ability to continue as a going concern.<figure class="image"><img src="https://news.stocktwits-cdn.com/RGC_stock_chart_jpg_b4d92bf445.webp" alt="RGC stock performance from Jan. 1, 2025 to Jan. 7, 2025" width="1516" height="417"><figcaption>RGC stock performance from Jan. 1, 2025 to Jan. 7, 2025 | Koyfin</figcaption></figure><h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits regarding Regencell Bioscience was trending in the ‘bullish’ territory at the time of writing.One bullish user thinks that traders shorting the stock are in “huge trouble now.”<stembedurl>https://stocktwits.com/elbardinnyo/message/641188884</stembedurl>Another user said they treat it as a momentum-only stock.<stembedurl>https://stocktwits.com/Faniabh/message/641180065</stembedurl><h2 class="st-heading-2">RGC’s Going Concern Flag</h2>In a filing with the U.S. Securities and Exchange Commission in October 2025, the company said that there is a “substantial doubt” about its ability to continue as a going concern.It added that this indicates the company may be required to curtail or discontinue its operations in the future.“If we discontinue our operations, you may lose all of your investment,” Regencell said, adding that it anticipates incurring additional losses before realizing any revenues. In the 2025 and 2024 fiscal years, Regencell reported a net loss of $3.58 million and $4.36 million, respectively.Regencell is an early-stage company focusing on research, development, and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder.<a href="https://stocktwits.com/symbol/RGC">RGC stock</a> is up 152% year-to-date.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-is-hele-stock-falling-today/cmUb4SeR4Po">HELE Stock Slides Pre-market As Tariff Headwinds Trigger FY26 Earnings Guidance Cut</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a trending stock chart.

Regencell shares are up nearly 218% since October 31, despite the company flagging a “substantial doubt” about its ability to continue as a going concern.

Why Is RGC Stock Soaring Today?

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$6.71
Prev Close	$6.86
Open	$6.89
Dividend Yield	0.00%
50-Day Moving Average	$6.83
Beta	0.24
Avg. Volume	172,009.01
PE Ratio	-284.32

52-Week High	$69.00
52-Week Low	$4.51
Market Capitalization	$3.33B
EPS (Annual)	-$0.0237
Price to Book	249.26
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

RGC Fundamentals